Clinical trial · Interventional
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
Phase II Trial of Salvage Chemotherapy With Temozolomide in Combination With Topotecan for Primary CNS Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sub-Investigator reloacted to another institution
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as temozolomide and topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving temozolomide together with topotecan works in treating patients with primary CNS lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Central Nervous System Tumors | Central Nervous System Neoplasm | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| temozolomide | Drug | Temozolomide | ALIAS |
| topotecan hydrochloride | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Temozolomide, Topotecan
- description
- Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
- interventionNames
- Drug: temozolomide
- Drug: topotecan hydrochloride
Primary outcomes (1)
- measure
- Rate of complete radiologic response (CR)
- timeFrame
- July 2006
Secondary outcomes (4)
- measure
- Median overall survival
- timeFrame
- July 2006
- measure
- Failure-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria DISEASE CHARACTERISTICS: * Histologically confirmed primary CNS lymphoma at initial diagnosis * Measurable tumor by radiography * Failed\* OR is not a candidate for first-line high-dose systemic methotrexate-based chemotherapy with or without radiotherapy NOTE: \*Failure is defined as relapse, progression, or failure to achieve a complete response PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 50-100% Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL Hepatic * SGOT and SGPT ≤ 3 times upper limit of normal * Bilirubin ≤ 2.0 mg/dL Renal * Creatinine clearance \> 40 mL/min Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No known allergy to temozolomide or topotecan * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer in complete remission * No other major medical illness or psychiatric impairment that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent prophylactic growth factors Chemotherapy * See Disease Characteristics * At least 6 weeks since prior nitrosoureas * At least 2 weeks since prior methotrexate Endocrine therapy * Not specified Radiotherapy * See Disease Characteristics Surgery * Not specified Other * Recovered from all prior therapy * At least 4 weeks since prior non-nitrosourea cytotoxic drugs (except methotrexate) * At least 4 weeks since prior systemic investigational agents * At least 2 weeks since prior non-cytotoxic antitumor drugs * No other concurrent antitumor therapy EXCLUSION CRITERA 1. Patients who are pregnant or breastfeeding, or females of childbearing potential not using adequate contraception. 2. Known allergy to temozolomide or topotecan. 3. Severe vomiting or other inability to administer medications orally. 4. Major medical illnesses or psychiatric impairment that in the investigator's opinion will prevent administration or completion of the protocol therapy and/or will interfere with follow-up.
References
Publications (0)
Data not yet available